Celgene pulls plug on Crohns disease trials
Celgene is abandoning latestage testing of its experimental drug mongersen for Crohn’s disease after a Data Monitoring Committee concluded that it would be futile to continue.
View ArticleCelgene axes gene silencing drug in Crohn's
Celgene has axed its gene silencing therapy in Crohns disease after an analysis of a phase 3 trial showed the drug was unlikely to produce results.The decision looks likely to end the development...
View ArticleCelgene Weighs Fate of Crohn's Candidate GED0301 after Phase III Failures
Celgene said it will weigh whether to continue its clinical program for GED0301 mongersenfor which it committed up to $2.6 billion in 2014following the Crohns disease candidates failure in a Phase III...
View ArticleCelgene IBD Pipeline In Question As Mongersen Crohns Disease Trial Ends
Celgene will stop latestage testing of its investigative therapy mongersen for Crohns disease after a data monitoring committee said it...&160;&160;&160;
View ArticlePharma Q3 Results Preview Novartis Lilly Amgen GSK
There&39;s optimism around Novartis as it heads into its final quarter with Joe Jimenez in charge while Lilly faces impending...&160;&160;&160;
View ArticleBillion dollar deal turns sour as Crohn's disease candidate fails
Shares in New Yorklisted Celgene are down a tenth today following yesterdays news that the company
View ArticleNorth America Injectable Drug Delivery Market Industry Trends and Forecast to...
Synopsis North America injectable drug delivery market is expected to reach USD 354.5 billion by 2024 from USD 154.0 billion in 2016 at a CAGR of 11.0 in the forecast period 2017 to 2024. The report...
View ArticleProtein regulates vitamin A metabolic pathways prevents inflammation
Case Western Reserve University A team of researchers from Case Western Reserve University School of Medicine have discovered how uncontrolled vitamin A metabolism in the gut can cause harmful...
View ArticleTiGenix granted Orphan Drug Designation from the U.S. FDA for Cx601
PRESS RELEASE TiGenix granted Orphan Drug Designation from the U.S. FDA for Cx601 Leuven BELGIUM October 23 2017 700h CEST TiGenix NV Euronext Brussels and NASDAQ TIG an advanced biopharmaceutical...
View ArticleCelgene to stop clinical trials of Crohn's disease drug GED0301
Celgene has decided to stop the clinical trials of Crohn's disease drug GED0301 mongersen due to lack of meaningful results.
View ArticleMongersen Fails
Readers may recall a post here last year about an odd trial of an antisense drug for Crohn&8217;s disease. Celgene had acquired the drugÂmongersen GED301 from Nogra Pharma of Ireland back in 2014...
View ArticleCelgenes $710M Gamble On A Crohns Disease Drug Ends In Defeat
NewsAmerican biotech company Celgene recently announced that it has prematurely halted a phase three clinical trial for a drug called mongersen.
View ArticleFDA Grants Belgian Crohns Disease Candidate Orphan Designation
TiGenix has seen its Crohns disease candidate receive orphan drug designation after agreeing on a global Phase III trial. TiGenixÂexploits the antiinflammatory properties of donorderived stem cells to...
View ArticleFDA grants orphan designation to TiGenixs Cx601 for Crohns disease
The US Food and Drug Administration FDA has granted orphan drug designation to Belgian biopharmaceutical firm TiGenixs Cx601 to treat patients with fistulizing Crohns disease.
View ArticleEPIOMIC EPIDEMIOLOGY SERIES GRAVES' DISEASE FORECAST IN 23 MAJOR MARKETS...
Black Swan Analysis Epiomic Epidemiology Series Forecast Report on Graves' Disease in 23 Major MarketsGraves' disease is an autoimmune disease of the thyroid gland in which the thyroid attacked by the...
View ArticleWie gro ist der Flop von Celgene
Celgene WKN881244 hat diese Woche zwei GED301 Morbus CrohnStudien abgeschlossen nachdem ein Zwischenblick auf die Daten unabhngiger Beobachter enttuschend war. Das Scheitern im Sptstadium ...
View ArticleTiGenixs Crohn's fistulas treatment wins orphan drug status
FDA designation follows positive trial results
View ArticleU.S. FDA grants orphan drug designation to glepaglutide for the treatment of...
Company announcement No. 482017 U.S. FDA grants orphan drug designation to glepaglutide for the treatment of short bowel syndrome Copenhagen Denmark October 24 2017 The U.S. Food and Drug...
View ArticleTiGenix's Crohn's disease fistula drug gains FDA orphan status
TiGenix's Cx601 which is being developed as a treatment for complex perianal fistulas in patients with Crohn's disease who h More
View Article